Mitesh

The Department of Health and Social Care (DHSC) has today (20/05/2026) confirmed the following list of price concessions for May 2026: Drug Pack size Price concession Alfuzosin 2.5mg tablets 60 £7.64 Aspirin 75mg tablets 28 £1.63 Benzydamine 0.15% mouthwash sugar free 300 £3.15 Bisoprolol 1.25mg tablets 28 £4.79 Carvedilol 3.125mg tablets 28 £1.91 Chloramphenicol 1% eye [...]

The post May 2026 Price Concessions 2nd Update appeared first on Community Pharmacy England.

The MHRA has reviewed the evidence for finasteride and dutasteride and the risk of suicidal thoughts and behaviours and has recommended further measures to minimise this risk. The MHRA has reviewed the evidence for finasteride and dutasteride and the risk of suicidal thoughts and behaviours and has recommended further measures to minimise this risk. The product [...]

The post MHRA Drug Safety Update: Finasteride and Dutasteride – updated safety warnings appeared first on Community Pharmacy England.

The following price concessions granted in April 2026 have rolled over to May 2026: Drug  Pack size Price concession Candesartan 4mg tablets 7 £0.75 Labetalol 200mg tablets 56 £17.87 Lacidipine 4mg tablets 28 £1.95 Ramipril 2.5mg capsules 28 £0.94 Sumatriptan 100mg tablets 6 £1.10 Please note any rolled over prices can be adjusted upwards if [...]

The post Rolled Over Price Concessions For May 2026 appeared first on Community Pharmacy England.

24 new products (including those with multiple flavours) have been added to the ‘Drugs for which Discount is Not Deducted’ (DND) list from 1 May 2026. Community Pharmacy England, on behalf of pharmacy owners, applied to the Department of Health and Social Care (DHSC) and the NHS Business Services Authority (NHSBSA) for these products to [...]

The post 24 products added to the Discount Not Deducted (DND) list from May 2026 appeared first on Community Pharmacy England.

Nasal decongestant sprays and drops containing xylometazoline hydrochloride / oxymetazoline hydrochloride: increased risk of rebound congestion, rhinitis medicamentosa, and tachyphylaxis with overuse. There have been reports of worsening nasal congestion (rebound congestion) when the effects of nasal decongestant sprays or drops containing xylometazoline hydrochloride and oxymetazoline hydrochloride, referred to hereafter as ‘xylometazoline’ and ‘oxymetazoline’, wear [...]

The post MHRA Drug Safety Update: Nasal decongestant sprays and drops containing xylometazoline hydrochloride / oxymetazoline hydrochloride appeared first on Community Pharmacy England.